[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neovascular-wet-age-related-macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neovascular-wet-age-related-macular-degeneration":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,77,103,129,166,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100637618","phase-1-phase-1b2a-study-of-eyc-0305-in-patients-with-neovascular-age-related-macular-degeneration-100637618",false,"NCT07587515","Phase 1b\u002F2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration","Open-Label, Multiple Ascending Dose Phase 1b\u002F2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration","OVERTURE","Inclusion Criteria:\n\n* Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria\n* Willing and able to comply with clinic visits and study-related procedures\n* Provide signed informed consent\n\nExclusion Criteria:\n\n* Known hypersensitivity or known allergy that would preclude study drug administration\n* Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access\n* Uncontrolled diabetes mellitus\n* History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit\n* Renal failure, dialysis, or history of renal transplant\n* Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion\n* Pregnant or breastfeeding women","ALL","50 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This Phase 1b\u002F2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.",[28],"Neovascular (Wet) Age-Related Macular Degeneration",[30,31,32,33,34,35,36],"EYC-0305","TransCon aVEGF","wet AMD","neovascular AMD","treatment naive","Eyconis","anti-VEGF","RECRUITING","2026-06-25",{"date":40,"type":41},"2026-06-29","ACTUAL",{"date":43,"type":41},"2026-05-19",{"date":45,"type":21},"2028-05",{"name":47,"class":48},"Eyconis INC.","OTHER",5,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100618219","ai-vs-physician-for-anti-vegf-decision-making-an-rct-100618219","NCT07328776","AI vs. Physician for Anti-VEGF Decision-Making: An RCT","An Artificial Intelligence System for Anti-VEGF Treatment Decisions in Retinal Diseases: A Randomized Controlled Trial","Inclusion Criteria:\n\nPatients with a diagnosis of nAMD, DME, and RVO; Patients who have completed the loading-dose treatment of anti-VEGF agents; Patients who were willing to participate and provided written informed consent.\n\nExclusion Criteria:\n\nRefusal to undergo OCT testing; Refusal to complete the 3-month follow-up period; Screening for a history of intraocular surgery within the past 6 months; Subjects with severe systemic diseases, intellectual developmental disorders, psychiatric illnesses, etc.","85 Years",{"count":59,"type":21},200,[61],"NA","We developed an artificial intelligence system, called QiLin, which was designed to assist anti-VEGF treatment decisions in retinal diseases. QiLin was trained and validated via over 20,000 optical coherence tomography images from multicenter datasets, demonstrating strong performance on both internal and external validation. To evaluate its real-world clinical utility, we conducted a randomized controlled trial that rigorously compares the accuracy of treatment decisions between a physician-only arm and an AI-assisted physician arm.",[64,65,28],"DME","Retinal Vein Occlusion (RVO)","NOT_YET_RECRUITING","2026-05-18",{"date":69,"type":41},"2026-05-22",{"date":71,"type":21},"2026-05-25",{"date":73,"type":21},"2026-10-15",{"name":75,"class":48},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100636608","effectiveness-of-multidisciplinary-protocolised-interventions-on-ivt-non-adherence-rates-100636608","NCT07567898","Effectiveness of Multidisciplinary Protocolised Interventions on IVT Non-adherence Rates","The Effectiveness of Multidisciplinary Protocolised Interventions to Reduce Non-adherencE Rates (ADHERE) in Patients With Chronic Macula Diseases Receiving Intravitreal Injections: A Randomised Controlled Trial","ADHERE","Inclusion Criteria:\n\n* Patients with chronic macula disease including those diagnosed with nAMD and DME, who require IVT.\n* This would include treatment naive patients (no IVT in either eye the last 6 months) and previously treated patients who have had IVT in either eye in the last 6 months and require further IVT treatment at the baseline study visit in either eye.\n* Able to provide informed consent and must consent to undergoing the MPI intervention.\n* Speak English or Mandarin.\n* Must be a Singapore resident.\n\nExclusion Criteria:\n\n* Patients who are unwilling or unable to perform CAT testing.\n* Unable to provide informed consent.\n* Significant eye pathology such as cornea problems, glaucoma, or other retinal diseases that may substantially affect vision.\n* Do not speak English or Mandarin fluently.\n* Cognitive impairment (as assessed using 6CIT).\n* Obvious observable physical or hearing disabilities that prevents them from completing the CAT questionnaire and undergoing MPI effectively.",{"count":59,"type":21},[61],"The purpose of this research study is to test whether a personalised care approach improves adherence compared to standard care. Many patients with macular diseases like age-related macular degeneration and diabetic macular edema need regular eye injections to protect their vision. However, some do not adhere to their treatment appointments, risking further vision loss.\n\nYou were selected as a possible participant in this research study because you have been diagnosed with neovascular age-related macular degeneration (nAMD) or diabetic macula edema (DME) requiring intravitreal injection treatment (IVT).\n\nThis research study targets to recruit 200 participants from the Singapore National Eye Centre.\n\nThis study comprises two cohort groups: Cohort 1(Suboptimal CAT scores\u002F Randomized Control trial) and Cohort 2 (Optimal CAT scores\u002FObservation).\n\nIf you agree to take part in this study, the research coordinator will obtain your written consent before proceeding with the study procedures. You will be required to complete CAT assessment (via remote or administered in clinic) and assigned to cohort 1 or cohort 2 based on CAT scores result. If you are assigned to cohort 1, you will be randomly allocated to either the personalized multi-disciplinary protocolized intervention (MPI) or standard care group. Randomization means assigning you to one of two groups by chance, like tossing a coin or rolling a dice.\n\n* MPI group: You will complete a specialized computerized adaptive testing (CAT) quality of life questionnaire. Based on the domain specific scores, you will receive a medical consultation and a referral to nurse educators, optometrists, occupational therapists, or social workers.\n* Standard care group: If you are allocated to this group, you will receive standard care, where doctors make treatment decisions without using the CAT results.\n\nIf you are assigned to cohort 2, you will be placed under prospective observation and undergo routine clinical care.",[89,28,90],"Diabetic Macular Edema","Intravitreal Injection",[92,93],"ADHERE, Macular diseases, Intravitreal injections.","neovascular age-related macular","2026-04-28",{"date":96,"type":41},"2026-05-05",{"date":98,"type":21},"2026-04",{"date":100,"type":21},"2028-09",{"name":102,"class":48},"Singapore Eye Research Institute",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100635779","phase-2-safety-and-efficacy-of-aiv007-periocular-injection-in-patients-with-neovascular-age-related-macular-degeneration-100635779","NCT07557121","Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration","A Phase 2, Multicenter, Randomized, Active-controlled Trial of the Safety and Efficacy of AIV007 by Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration","Inclusion Criteria:\n\n* Previously treated neovascular (wet) age-related macular degeneration (nAMD)\n* Responsive to prior intravitreal anti-VEGF therapy\n* Study eye at screening must have an ETDRS letter score greater than 35 (20\u002F200 Snellen equivalent)\n* Active choroidal neovascularization lesion in the study eye secondary to nAMD.\n* Central subfield thickness in the study eye of less than or equal to 370 microns.\n* Compliance to all study protocol requirements\n\nExclusion Criteria:\n\n* Study eye has had previous treatment with cell therapy, brachytherapy, and\u002For gene therapy\n* History of uncontrolled intraocular pressure\n* Presence of any clinically significant epiretinal membrane, vitreomacular traction, subfoveal atrophy (including RPE degeneration), RPE tear in the study eye\n* History of vitreoretinal surgery, corneal transplant, glaucoma surgery in the study eye or cataract surgery within 3 months before screening visit\n* History of vitreous hemorrhage within 3 months prior to screening visit in the study eye\n* A clinically significant cataract (including PSC) likely to affect trial outcomes (i.e., vision) in the study eye\n* Anterior chamber intraocular lens, aphakia, or violation of the posterior capsule in the study eye; prior Nd:YAG laser posterior capsulotomy in association with posterior intraocular lens implantation is allowed provided it occurred at least 30 days before the screening visit\n* Any active bacterial, viral, fungal or parasitic ocular or periocular infection or any history of uveitis in either eye\n* Intraretinal fluid (IRF) in the proposed study eye of less than 30 µm confirmed by the CRC following the screening visit",{"count":111,"type":21},35,[25],"The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile.\n\nParticipants will receive either a periocular injection of AIV007 or intravitreal injection of Eylea (control arm) to the study eye and return to the clinic monthly for safety and efficacy observations and\u002For continued treatment. Participants may receive additional treatment(s) if they meet specified criteria.",[28],[32,36,116,117,118],"periocular","Eylea","tyrosine kinase inhibitor","2026-04-23",{"date":121,"type":41},"2026-04-29",{"date":123,"type":21},"2026-07-01",{"date":125,"type":21},"2027-08-23",{"name":127,"class":128},"AiViva BioPharma, Inc.","INDUSTRY",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100454417","phase-1-4d-150-in-patients-with-neovascular-wet-age-related-macular-degeneration-100454417","NCT05197270","4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration","A Phase 1\u002F2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration","* 50 years of age\n\nIndividuals eligible to participate in the trial must meet the following inclusion criteria:\n\n1. ≥50 years of age\n2. Diagnosed with CNV secondary to AMD (confirmed by reading center)\n3. BCVA ≥34 ETDRS letters (\\~20\u002F200) in the contralateral eye, and BCVA in the study eye:\n4. Central subfield thickness (CST) and\u002For presence of subretinal or intraretinal fluid requiring continued anti-VEGF therapy in the study eye, as assessed by SD-OCT; and confirmed by a reading center):\n5. Study eye amenable to IVT injection\n6. Ability to perform tests of visual and retinal function and structure, and ability to comply with other protocol-specified procedures\n7. Currently receiving anti-VEGF treatment (e.g. ranibizumab, aflibercept, faricimab or bevacizumab) in the study eye AND has demonstrated a clinical response consistent with anti-VEGF activity within 12 months prior to screening:\n\n   Note: Day -7 aflibercept will be administered ≥ 4 weeks from last IVT anti-VEGF\n8. Subjects receiving 4D-150 agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period\n9. Medical records available to document history of anti-VEGF therapy (dates, drugs, and dosage) for a minimum of 12 months prior to Screening\n10. Provide written informed consent.\n\nContralateral Eye Sub-study-Specific Criteria:\n\n1. Received 4D-150 in study eye-1 at least 6 months prior to Contralateral Substudy Screening Visit NOTE: Subjects who received 4D-150 in study eye-1 as part of the Shedding Substudy are also eligible to participate in the Contralateral Eye Substudy only after biological samples from all matrices were at or below the limit of quantitation for vector genomes in at least 3 consecutive measurements AND at least 6 months has passed since 4D-150 administration to study eye-1.\n2. Macular neovascularization (MNV) secondary to AMD in study eye-2 as assessed on historical images at any time by SD-OCT (required) and FA when available or fundus photography when available or at screening based on SD-OCT, FA and fundus photography (confirmed by the reading center)\n3. History of at least 1 anti-VEGF injection in study eye-2 within 6 months prior to Screening (last anti-VEGF injection must be at least 28 days prior to Screening) AND has demonstrated a clinical response consistent with anti-VEGF activity by historical OCT at any time point prior to screening with confirmed response by the reading center (Screening OCT can be confirmatory)\n4. BCVA between 25 and 83 ETDRS letters, inclusive (20\u002F320 20\u002F25 Snellen) in study eye-2\n5. Study eye-2 amenable to IVT injection\n6. BCVA ≥34 ETDRS letters (\\~20\u002F200) in the previously treated study eye-1\n7. Ability to comply with protocol-specified procedures and visits, in the Investigator's judgment\n8. Agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to study eye-2 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period\n9. Provide written informed consent.\n\nShedding Substudy-specific Inclusion Criteria:\n\n1. ≥50 years of age\n2. Diagnosed with MNV secondary to AMD as assessed on historical images at any time by spectral domain optical coherence tomography (SD-OCT) (required) and fluorescein angiography when available or fundus photography when available or at screening based on SD-OCT, FA and fundus photography (confirmed by Reading Center)\n3. Best corrected visual acuity (BCVA) between 10 and 83 ETDRS letters, inclusive (\\~20\u002F640 and 20\u002F25, respectively) in the study eye at Screening\n4. BCVA ≥34 ETDRS letters (\\~20\u002F200) in the contralateral eye\n5. Currently receiving anti-VEGF treatment (e.g. ranibizumab, aflibercept, faricimab or bevacizumab) in the study eye; minimum of 1 injection within the last 6 months (last anti-VEGF injection must be at least 28 days prior to screening) AND has demonstrated a clinical response consistent with anti-VEGF activity by historical OCT at any time prior to screening with confirmed response by the reading center (Screening OCT can be confirmatory)\n6. Study eye amenable to IVT injection\n7. Ability to perform tests of visual and retinal function and structure, and ability to comply with other protocol-specified procedures, in the Investigator's judgment\n8. Agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period\n9. Provide written informed consent.",{"count":137,"type":21},215,[24,25],"Phase 1\u002F2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.\n\nSubstudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.",[28],[142,143,144,145,146,147,148,149,150,151,152,153,154,155],"Age-related macular degeneration","AMD","Exudative AMD","Exudative age-related macular degeneration","Neovascular AMD","Neovascular age-related macular degeneration","Wet age-related macular degeneration","Wet macular degeneration","Wet AMD","wAMD","Retinal gene therapy","Intravitreal gene therapy","Genetic Medicine","Ocular Gene Therapy","2026-02-10",{"date":158,"type":41},"2026-02-12",{"date":160,"type":41},"2021-12-09",{"date":162,"type":21},"2031-01",{"name":164,"class":128},"4D Molecular Therapeutics",25,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":176,"studyType":177,"phases":4,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":187,"locationsCount":4},"100574462","the-effect-of-phacoemulsification-on-the-macular-changes-in-patients-with-neovascular-age-related-macular-degeneration-100574462","NCT06759597","The Effect of Phacoemulsification on the Macular Changes in Patients with Neovascular Age-related Macular Degeneration","Macular Changes After Phacoemulsification in Patients with Neovascular AMD","it does not","Inclusion Criteria:Subjects included in this study aged above 50 and presented for routine check up after undergoing phacoemulsification:\n\n* Above 50 years old\n\n  * not diabetic individuals\n  * wet ARMD\n\nExclusion Criteria:\n\n* intraoperative complications\n\n  * Eyes with diseases predisposing them for postoperative macular edema, preexisting macular edema, and eyes that developed cystoid macular edema\n  * active ocular inflammation or infection \\_glaucoma\n  * A preoperatively worsened VA regardless phE\n  * ocular trauma\n  * patients with central retinal ischemia\n  * previous vitrectomy\n  * dry amd",{"count":175,"type":21},50,"1 Month","OBSERVATIONAL","The macula has a very high concentration of photoreceptor cells - the cells that detect light. They send signals to the brain, which interprets them as images. The rest of the retina processes our peripheral, or side vision To explore whether cataract surgery evokes development or relapse of choroidal neovascularization (CNV) in wet age-related macular degeneration (AMD) patients followed for a 1-year postoperative period",[180],"Neovascular (wet) Age-Related Macular Degeneration","2024-12-30",{"date":183,"type":41},"2025-01-06",{"date":185,"type":21},"2025-02-01",{"date":98,"type":21},{"name":188,"class":48},"Assiut University",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":177,"phases":4,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":212},"100542725","a-long-term-follow-up-study-to-evaluate-skg0106-in-the-treatment-of-patients-with-namd-100542725","NCT06346600","A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD","A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)","Inclusion Criteria:\n\nSubjects who only meet all of the following criteria are eligible for this study:\n\n* nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection;\n* Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study\n\nExclusion Criteria:\n\n* Subjects who are judged by the investigator unsuitable for this study",{"count":197,"type":21},83,"This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.",[200],"Neovascular (Wet) Age-related Macular Degeneration",[202,151],"nAMD","2024-04-03",{"date":205,"type":41},"2024-04-04",{"date":207,"type":41},"2024-04-02",{"date":209,"type":21},"2031-03",{"name":211,"class":128},"Skyline Therapeutics",10]